A modified weighted log-rank test for confirmatory trials with a high proportion of treatment switching

Abstract

In confirmatory cancer clinical trials, overall survival (OS) is normally a primary endpoint in the intention-to-treat (ITT) analysis under regulatory standards. After the tumor progresses, it is common that patients allocated to the control group switch to the experimental treatment, or another drug in the same class. Such treatment switching may dilute the relative efficacy of the new drug compared to the control group, leading to lower statistical power. It would be possible to decrease the estimation bias by shortening the follow-up period but this may lead to a loss of information and power. Instead we propose a modified weighted log-rank test (mWLR) that aims at balancing these factors by down-weighting events occurring when many patients have switched treatment. As the weighting should be pre-specified and the impact of treatment switching is unknown, we predict the hazard ratio function and use it to compute the weights of the mWLR. The method may incorporate information from previous trials regarding the potential hazard ratio function over time. We are motivated by the RECORD-1 trial of everolimus against placebo in patients with metastatic renal-cell carcinoma where almost 80% of the patients in the placebo group received everolimus after disease progression. Extensive simulations show that the new test gives considerably higher efficiency than the standard log-rank test in realistic scenarios.

An Overview of Introductory and Advanced Survival Analysis Methods in Clinical Applications: Where Have we Come so far?

“…In that case, the LR test should not be used due to an increased chance of a false negative result, and thus low statistical power (12). Since there is no specific path as to which test is used in each situation, in case of cross-over, a re-evaluation should be done, using weighted (51,52) or modified LR tests (53,54), which we will talk about in more detail below in case of lack of the PH assumption. However, as the LR test is a test of statistical significance, it is evident that it cannot estimate the size of the difference between groups and the confidence interval (1,44).…”

New Test for the Comparison of Survival Curves to Detect Late Differences

“…) [17]. Having two weighted log-rank statistics T w and T w , the ARE of T w relative to T l as proposed by Jiménez et al [18] is given by…”

The Inverse Log-Rank Test: A Versatile Procedure for Late Separating Survival Curves

“…When the curves extend beyond the point of diminishing treatment effect and then crossover, this poses interpretational challenges that may be best handled as a post hoc stratified analyses. The latter scenario merits exploring the underlying reasons for the crossing-over and any subgroup effects (e.g., potential treatment switching) before reaching any conclusions [7,90]. In the case of crossing hazards, a two-sample semiparametric procedure has been proposed as an alternative analytic approach [91].…”